Tandem Diabetes Care (TNDM)

• Market cap: $1.1B
• 1 day: 0.48%
• 5 days: 0.90%
• 1 month: -12.06%
• 3 months: -54.47%
• 6 months: -47.93%
• Year to date: -52.99%
• 1 year: -54.07%
• 5 years: -78.88%
• 10 years: -87.38%
• Sector: Healthcare
• Industry: Medical Devices

About: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.

Employees: 2,650

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,442% more call options, than puts

Call options by funds: $114M | Put options by funds: $7.37M

57% more repeat investments, than reductions

Existing positions increased: 138 | Existing positions reduced: 88

0% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 5 (+0) [Q4]

1.84% less ownership

Funds ownership: 111.56% [Q3] → 109.72% (-1.84%) [Q4]

5% less funds holding

Funds holding: 328 [Q3] → 313 (-15) [Q4]

16% less capital invested

Capital invested by funds: $3.1B [Q3] → $2.6B (-$501M) [Q4]

16% less first-time investments, than exits

New positions opened: 41 | Existing positions closed: 49

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $20 19% upside
• Avg. target: $35 108% upside
• High target: $63 274% upside

9 analyst ratings

• positive: 3 33%
• neutral: 6 67%
• negative: 0 0%

Mizuho Anthony Petrone 45% 1-year accuracy 10 / 22 met price target	19% upside $20	Neutral Initiated	10 Apr 2025
Morgan Stanley Patrick Wood 50% 1-year accuracy 6 / 12 met price target	31% upside $22	Equal-Weight Downgraded	5 Mar 2025
Citigroup Joanne Wuensch 44% 1-year accuracy 18 / 41 met price target	42% upside $24	Neutral Downgraded	4 Mar 2025
Goldman Sachs David Roman 30% 1-year accuracy 6 / 20 met price target	42% upside $24	Neutral Maintained	3 Mar 2025
Wells Fargo Larry Biegelsen 27% 1-year accuracy 12 / 44 met price target	31% upside $22	Equal-Weight Downgraded	3 Mar 2025